Sera from patients with active systemic lupus erythematosus patients enhance the toll-like receptor 4 response in monocyte subsets

Table 1 Clinical findings in 22 patients with systemic lupus erythematosus (SLE)

	ASLE (n = 11)	ISLE (n = 11)
Mean SLEDAI scores	10.4 ± 4.1	1.5 ± 1.2
Mean time since diagnosis	6.6 ± 6.0	8.3 ± 4.9
Lupus nephritis	45.5 %	54.5 %
Neurolupus	0 %	18.2 %
Lupus arthritis	72.7 %	63.6 %
Hematological involvement	100 %	90.9 %
Lupus cutaneous involvement	72.7 %	72.7 %
Severe Lupus^a	45.5 %	54.5 %
Anti-dsDNA antibodies^b
Negative	0 %	27.2 %
Low positive	9.1 %	36.4 %
Moderate positive	18.2 %	27.3 %
High positive	72.7 %	9.1 %
Treatment
Hydroxychloroquine	90.9 %	90.9 %
Immunossupressants^c	54.5 %	36.4 %
Steroids^d	90.9 %	18.2 %
Low dose	40.0 %	100 %
Moderate dose	30.0 %	0 %
High dose	30.0 %	0 %

^aLupus severity in accordance with cumulative major organ involvement
^bAnti-dsDNA antibodies: low positive (<20 IU); moderate positive (20–50 IU); high positive (>50 IU)
^cazathioprine, mycophenolate mofetil, cyclosporine, tacrolimus, methotrexate, cyclophosphamide or rituximab
^dLow dose, up to 10 mg/day; moderate dose, 10–30 mg/day; high dose, more than 30 mg/day

ISSN: 1476-9255